| Literature DB >> 33513361 |
Shinpei Yoshida1, Takayuki Honjo2, Keita Iino2, Ryunosuke Ishibe2, Sylvia Leo2, Tomoka Shimada3, Teruhiko Watanabe4, Masaya Ishikawa4, Kazuya Maeda5, Hiroyuki Kusuhara5, Nobuaki Shiraki6, Shoen Kume7.
Abstract
We aimed to establish an in vitro differentiation procedure to generate matured small intestinal cells mimicking human small intestine from human-induced pluripotent stem cells (iPSCs). We previously reported the efficient generation of CDX2-expressing intestinal progenitor cells from embryonic stem cells (ESCs) using 6-bromoindirubin-3'-oxime (BIO) and (3,5-difluorophenylacetyl)-L-alanyl-L-2-phenylglycine tert-butyl ester (DAPT) to treat definitive endodermal cells. Here, we demonstrate the generation of enterocyte-like cells by culturing human iPSC-derived intestinal progenitor cells on a collagen vitrigel membrane (CVM) and treating cells with a simple maturation medium containing BIO, DMSO, dexamethasone, and activated vitamin D3. Functional tests further confirmed that these iPSC-derived enterocyte-like cells exhibit P-gp- and BCRP-mediated efflux and cytochrome P450 3A4 (CYP3A4)-mediated metabolism. We concluded that hiPS cell-derived enterocyte-like cells can be used as a model for the evaluation of drug transport and metabolism studies in the human small intestine.Entities:
Keywords: drug development; enterocyte; human model; induced pluripotent stem cells; intestine; in vitro differentiation; pharmacokinetics
Year: 2021 PMID: 33513361 PMCID: PMC7878837 DOI: 10.1016/j.stemcr.2020.12.017
Source DB: PubMed Journal: Stem Cell Reports ISSN: 2213-6711 Impact factor: 7.765